author-photo

Evan A. Stein

University of Cincinnati
Medpace

404

Papers

34236

Citations

Citation Trend

Filter By

Papers (404) Sort By

Journal Conference Others

Abstract 13280: apoB-Containing Lipoproteins and Risk of Myocardial Infarction: Distinguishing Between Particle Concentration, Content, and Type

2021 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

2021 JAMA Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
Results of a 52 week open-label phase 2B study to assess long-term safety, immunogenicity and LDL-C efficacy of monthly dosing with LIB003 a novel anti-PCSK9 recombinant fusion protein

2020 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (0)
EFFICACY AND SAFETY OF A 52 WEEK OPEN LABEL PHASE 2B EXTENSION TRIAL WITH MONTHLY DOSING OF AN ANTI-PCSK9 SMALL BINDING PROTEIN

2020 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia

2020 Annals of Internal Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program.

2020 Arteriosclerosis, Thrombosis, and Vascular Biology
Show All
- Source
- Cite
- Save
Citations (1)
Ldl-C Lowering Among Patients With Ldl-C Above 4.9 Mmol/L And Features Suggesting A Genetic Vulnerability To Cardiovascular Disease: Analyses From The 4s Trial

2019 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (0)
Cascade screening for familial hypercholesterolemia in south africa reveals a significant number of subjects with more than one fh mutation: the wits find-fh program.

2019 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study

2019 Circulation
Show All
- Source
- Cite
- Save
Citations (2)
Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

2019 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (9)